• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Impurity C of Alfacalcidol Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5753322

Impurity of Alfacalcidol is an impurity of Alfacalcidol. Alfacalcidol is a non-selective VDR activator medication. More details

Please Inquire
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Impurity C of Alfacalcidol, Inhibitor
Full Product Name
Impurity C of Alfacalcidol
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
575.78
Solubility
<1mg/ml refers to the product slightly soluble or insoluble
Formula
C35H49N3O4
SMILES
O[C@@H]1CC(C2C=C3[C@@](CC[C@@H]4[C@@H](CCCC(C)C)C)([H])[C@]4(C)CCC3N(C(N5C6=CC=CC=C6)=O)N2C5=O)=C(C)[C@@H](O)C1
CAS Number
82266-85-1
Target & IC50
Others

Structure of Impurity C of Alfacalcidol, inhibitor

Impurity C of Alfacalcidol Inhibitor – Cat# MBS5753322

Product References and Citations for Impurity C of Alfacalcidol, inhibitor

Shiraishi et al (2000) Alfacalcidol inhibits bone resorption and stmulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. Journal of Bone and Mineral Research. 15 770.
Shiraishi et al (2000) Alfacalcidol inhibits bone resorption and stmulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. Journal of Bone and Mineral Research. 15 770.
Ringe JD, Schacht E. et al. Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int. 2004 Jul;24(4):189-97.
Ringe JD, Schacht E. et al. Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int. 2004 Jul;24(4):189-97.
Ivarsen P, Povlsen JV, Christensen KL.Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study.Scand J Urol Nephrol. 2012 Jun 25.
Ivarsen P, Povlsen JV, Christensen KL.Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study.Scand J Urol Nephrol. 2012 Jun 25.
Rianthavorn P, Pisutikul K, Deekajorndech T, Tepmongkol S, Suphapeetiporn K.Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone.J Pediatr Endocrinol Metab. 2012;25(3-4):307-12.
Rianthavorn P, Pisutikul K, Deekajorndech T, Tepmongkol S, Suphapeetiporn K.Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone.J Pediatr Endocrinol Metab. 2012;25(3-4):307-12.

Other Notes

Small volumes of Impurity C of Alfacalcidol, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Impurity C of Alfacalcidol purchase

MBS5753322 is an inhibitor targeting Impurity C of Alfacalcidol.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000